報價延遲最少15分鐘:2025/01/12 03:55 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.67 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.61/0.21
|
|
企業價值
2.49B
|
| 資產負債 |
|
每股賬面淨值
-2.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
331.41M
|
|
每股收益
1.53
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:55 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |